PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
PepGen Inc. (PEPG)
Company Research
Source: GlobeNewswire
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PGN-EDODM1, an investigational candidate for the treatment of myotonic dystrophy type 1 (DM1). “Receiving Fast Track designation from the FDA for PGN-EDODM1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the DM1 community,” said James McArthur, Ph.D., President and CEO of PepGen. “Patients with DM1 currently have no available treatment options that target the root cause of the disease, which leads to progressive neuromuscular symptoms and reduction in life expectancy. Following robust preclinical data, we are now evaluating PGN-EDODM1 in the ongoing FREEDOM-DM1 Phase 1 trial and
Show less
Read more
Impact Snapshot
Event Time:
PEPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PEPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PEPG alerts
High impacting PepGen Inc. news events
Weekly update
A roundup of the hottest topics
PEPG
News
- PepGen Inc. (NASDAQ: PEPG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.MarketBeat
- PepGen Inc. (NASDAQ: PEPG) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.MarketBeat
- PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire
- PepGen to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
PEPG
Earnings
- 5/14/24 - Beat
PEPG
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 144
- 5/14/24 - Form 10-Q
- PEPG's page on the SEC website